BACKGROUND: Limited data are available on interventions to reduce sexual risk behaviors and increase knowledge of HIV vaccine trial concepts in high-risk populations eligible to participate in HIV vaccine efficacy trials. METHODS: The UNITY Study was a 2-arm randomized trial to determine the efficacy of enhanced HIV risk-reduction and vaccine trial education interventions to reduce the occurrence of unprotected vaginal sex acts and increase HIV vaccine trial knowledge among 311 HIV-negative noninjection drug using women. The enhanced vaccine education intervention using pictures along with application vignettes and enhanced risk-reduction counseling consisting of 3 one-on-one counseling sessions were compared with standard conditions. Follow-up visits at 1 week and 1, 6, and 12 months after randomization included HIV testing and assessment of outcomes. RESULTS: During follow-up, the percent of women reporting sexual risk behaviors declined significantly but did not differ significantly by study arm. Knowledge of HIV vaccine trial concepts significantly increased but did not significantly differ by study arm. Concepts about HIV vaccine trials not adequately addressed by either condition included those related to testing a vaccine for both efficacy and safety, guarantees about participation in future vaccine trials, assurances of safety, medical care, and assumptions about any protective effect of a test vaccine. CONCLUSIONS: Further research is needed to boost educational efforts and strengthen risk-reduction counseling among high-risk noninjection drug using women.
RCT Entities:
BACKGROUND: Limited data are available on interventions to reduce sexual risk behaviors and increase knowledge of HIV vaccine trial concepts in high-risk populations eligible to participate in HIV vaccine efficacy trials. METHODS: The UNITY Study was a 2-arm randomized trial to determine the efficacy of enhanced HIV risk-reduction and vaccine trial education interventions to reduce the occurrence of unprotected vaginal sex acts and increase HIV vaccine trial knowledge among 311 HIV-negative noninjection drug using women. The enhanced vaccine education intervention using pictures along with application vignettes and enhanced risk-reduction counseling consisting of 3 one-on-one counseling sessions were compared with standard conditions. Follow-up visits at 1 week and 1, 6, and 12 months after randomization included HIV testing and assessment of outcomes. RESULTS: During follow-up, the percent of women reporting sexual risk behaviors declined significantly but did not differ significantly by study arm. Knowledge of HIV vaccine trial concepts significantly increased but did not significantly differ by study arm. Concepts about HIV vaccine trials not adequately addressed by either condition included those related to testing a vaccine for both efficacy and safety, guarantees about participation in future vaccine trials, assurances of safety, medical care, and assumptions about any protective effect of a test vaccine. CONCLUSIONS: Further research is needed to boost educational efforts and strengthen risk-reduction counseling among high-risk noninjection drug using women.
Authors: Adaora A Adimora; Victor J Schoenbach; Dana M Bonas; Francis E A Martinson; Kathryn H Donaldson; Tonya R Stancil Journal: Epidemiology Date: 2002-05 Impact factor: 4.822
Authors: Daniel W Fitzgerald; Cécile Marotte; Rose Irene Verdier; Warren D Johnson; Jean William Pape Journal: Lancet Date: 2002-10-26 Impact factor: 79.321
Authors: Mary Spink Neumann; Wayne D Johnson; Salaam Semaan; Stephen A Flores; Greet Peersman; Larry V Hedges; Ellen Sogolow Journal: J Acquir Immune Defic Syndr Date: 2002-07-01 Impact factor: 3.731
Authors: Patricia Agre; Frances A Campbell; Barbara D Goldman; Maria L Boccia; Nancy Kass; Laurence B McCullough; Jon F Merz; Suzanne M Miller; Jim Mintz; Bruce Rapkin; Jeremy Sugarman; James Sorenson; Donna Wirshing Journal: IRB Date: 2003 Sep-Oct
Authors: Anne S Coletti; Patrick Heagerty; Amy R Sheon; Michael Gross; Beryl A Koblin; David S Metzger; George R Seage Journal: J Acquir Immune Defic Syndr Date: 2003-02-01 Impact factor: 3.731
Authors: Isabel Ruiz-Perez; Matthew Murphy; Guadalupe Pastor-Moreno; Antonio Rojas-García; Miguel Rodríguez-Barranco Journal: Am J Public Health Date: 2017-10-19 Impact factor: 9.308
Authors: Michael Weinborn; Jonson Moyle; Romola S Bucks; Werner Stritzke; Angela Leighton; Steven Paul Woods Journal: J Int Neuropsychol Soc Date: 2013-01-14 Impact factor: 2.892
Authors: Bethany White; Annie Madden; Margaret Hellard; Thomas Kerr; Maria Prins; Kimberly Page; Gregory J Dore; Lisa Maher Journal: Drug Alcohol Rev Date: 2012-11-01